| Naslov: | Real-world experience in treatment of patients with non-small-cell lung cancer with BRAF or cMET exon 14 skipping mutations |
|---|
| Avtorji: | ID Janžič, Urška, Univerzitetna klinika za pljučne bolezni in alergijo Golnik (Avtor)
ID Shalata, Walid (Avtor)
ID Szymczak, Katarzyna (Avtor)
ID Dziadziuszko, Rafal (Avtor)
ID Jakopović, Marko (Avtor)
ID Mountzios, Giannis (Avtor)
ID Płużański, Adam (Avtor)
ID Araújo, António (Avtor)
ID Charpidou, Andriani (Avtor)
ID Agbarya, Abed (Avtor) |
|---|
| Datoteke: |  URL - Izvorni URL, za dostop obiščite https://www.mdpi.com/1422-0067/24/16/12840
 PDF - Predstavitvena datoteka, prenos (305,90 KB)
MD5: CCADBE3C202C141A3B5DB28BD854F986
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
|
|---|
| Povzetek: | BRAF and cMET exon 14 skipping are rare mutations of NSCLC. The treatment sequence in these cases for the first and second line is not clear. An international registry was created for patients with advanced NSCLC harboring BRAF or cMET exon 14 skipping mutations, diagnosed from January 2017 to June 2022. Clinicopathological and molecular data and treatment patterns were recorded. Data on 58 patients, from eight centers across five countries, were included in the final analysis. We found that 40 patients had the cMET exon 14 skipping mutation and 18 had the BRAF V600E mutation. In total, 53 and 28 patients received first- and second-line treatments, respectively, among which 52.8% received targeted therapy (TT) in the first line and 53.5% in the second line. The overall response rate (ORR) and disease control rate (DCR) for first-line treatment with TT vs. other treatment such as immune checkpoint inhibitors ± chemotherapy (IO ± CT) were 55.6% vs. 21.7% (p = 0.0084) and 66.7% vs. 39.1% (p = 0.04), respectively. The type of treatment in first-line TT vs. other affected time to treatment discontinuation (TTD) was 11.6 m vs. 4.6 m (p= 0.006). The overall survival for the whole group was 15.4 m and was not statistically affected by the type of treatment (19.2 m vs. 13.5 m; p = 0.83). |
|---|
| Ključne besede: | non-small-cell lung cancer, BRAF V600 mutation, cMET exon 14 skipping mutation, real-world data, targeted therapy, first-line therapy |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Poslano v recenzijo: | 15.07.2023 |
|---|
| Datum sprejetja članka: | 15.08.2023 |
|---|
| Datum objave: | 16.08.2023 |
|---|
| Založnik: | MDPI, 2000- |
|---|
| Leto izida: | 2023 |
|---|
| Št. strani: | str. 1-14 |
|---|
| Številčenje: | Vol. 24, iss. 16, [article no.] 12840 |
|---|
| Izvor: | International journal of molecular sciences |
|---|
| PID: | 20.500.12556/DiRROS-27797  |
|---|
| UDK: | 616-006 |
|---|
| ISSN pri članku: | 1422-0067 |
|---|
| DOI: | 10.3390/ijms241612840 |
|---|
| COBISS.SI-ID: | 162782979 |
|---|
| Avtorske pravice: | © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
|---|
| Opomba: | Nasl. z nasl. zaslona;
Opis vira z dne 30. 8. 2023;
|
|---|
| Datum objave v DiRROS: | 25.02.2026 |
|---|
| Število ogledov: | 170 |
|---|
| Število prenosov: | 70 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
